Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$80.37 USD

80.37
10,721,135

+0.93 (1.17%)

Updated Aug 7, 2025 04:02 PM ET

After-Market: $80.27 -0.10 (-0.12%) 6:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments

by Zacks Equity Research

FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.

    Zacks Equity Research

    Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales

    by Zacks Equity Research

    Incyte (INCY) beat on revenues in the fourth quarter driven by an increase in Jakafi sales. The guidance for 2018 was also encouraging.

      Zacks Equity Research

      Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock

      by Zacks Equity Research

      Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, combined with the other party's Opdivo and Opdivo plus Yervoy.

        Zacks Equity Research

        Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?

        by Zacks Equity Research

        ImmunoGen (IMGN) advances with lead ovarian cancer candidate, mirvetuximab soravtansine. Moreover, combo therapies with the candidate for the indication are underway.

          Zacks Equity Research

          Merck (MRK) Halts Another Late Stage Study on Alzheimer's

          by Zacks Equity Research

          Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.

            Zacks Equity Research

            ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow

            by Zacks Equity Research

            ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.

              Zacks Equity Research

              The Zacks Analyst Blog Highlights: Merck, Goldman Sachs, Tesla, T-Mobile and Activision

              by Zacks Equity Research

              The Zacks Analyst Blog Highlights: Merck, Goldman Sachs, Tesla, T-Mobile and Activision

                Zacks Equity Research

                Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4

                by Zacks Equity Research

                Glaxo's (GSK) Q4 earnings and revenues beat estimates. In the event of Advair generic introduction in the U.S. market by mid 2018, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

                  Zacks Equity Research

                  Seattle Genetics (SGEN) Q4 Earnings & Revenues Top Estimates

                  by Zacks Equity Research

                  Seattle Genetics (SGEN) beats estimates on both counts on the back of strong Adcetris sales.

                    Zacks Equity Research

                    Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales

                    by Zacks Equity Research

                    Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.

                      Zacks Equity Research

                      Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre

                      by Zacks Equity Research

                      Gilead (GILD) topped earnings and sales expectations in the fourth quarter but the guidance for 2018 was disappointing due to further weakness in the HCV franchise.

                        Zacks Equity Research

                        Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study

                        by Zacks Equity Research

                        Bristol-Myers' (BMY) blockbuster drug, Opdivo, in combination with Yervoy, proves its worth again by demonstrating superiority in a lung cancer study.

                          Zacks Equity Research

                          AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018

                          by Zacks Equity Research

                          AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.

                            Zacks Equity Research

                            Merck (MRK) Tops on Q4 Earnings, Misses Sales, Stock Up

                            by Zacks Equity Research

                            Merck (MRK) beats estimates for earnings but misses the same for sales in Q4. The company issues an in-line outlook for 2018. Shares up in pre-market trading.

                              Zacks Equity Research

                              Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?

                              by Zacks Equity Research

                              Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.

                                Zacks Equity Research

                                Why Merck (MRK) Might Surprise This Earnings Season

                                by Zacks Equity Research

                                Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                  Zacks Equity Research

                                  Will Bristol-Myers' (BMY) Q4 Earnings Exceed Expectations?

                                  by Zacks Equity Research

                                  Bristol-Myers' (BMY) Opdivo is likely to play an instrumental role in driving fourth-quarter 2017 results.

                                    Zacks Equity Research

                                    Pfizer (PFE) Stock Falls Despite Q4 Earnings & Sales Beat

                                    by Zacks Equity Research

                                    Pfizer (PFE) beats expectations for both earnings and revenues in Q4 and issues an upbeat guidance for 2018. However, shares decline in pre-market trading.

                                      Zacks Equity Research

                                      Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?

                                      by Zacks Equity Research

                                      Merck's (MRK) new products like Keytruda and Bridion are likely to drive sales in the fourth quarter. However, headwinds remain in the form of genericization of key drugs and increasing competition.

                                        Zacks Equity Research

                                        Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

                                        by Zacks Equity Research

                                        Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                                          Zacks Equity Research

                                          Seattle Genetics Adcetris Performs Well Despite Competition

                                          by Zacks Equity Research

                                          Seattle Genetics (SGEN) is witnessing robust growth for its sole marketed product, Adcetris. However, over dependence on the same is a concern amid rising competition.

                                            Zacks Equity Research

                                            Will Pfizer (PFE) Surpass Estimates This Earnings Season?

                                            by Zacks Equity Research

                                            While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q4, genericization of key drugs and supply shortages in legacy Hospira products will hurt sales.

                                              Zacks Equity Research

                                              Is a Beat in the Cards for AbbVie (ABBV) in Q4 Earnings?

                                              by Zacks Equity Research

                                              Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q4.

                                                Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca

                                                by Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca

                                                  Zacks Equity Research

                                                  3 Large Cap Pharma Stocks to Beat Earnings This Quarter

                                                  by Zacks Equity Research

                                                  The fourth-quarter outlook for Pharma stocks looks bright.